Article Detail - JF Part A
MolDX: Molecular Testing for Solid Organ Allograft Rejection; Billing and Coding: MolDX: Molecular Testing for Solid Organ Allograft Rejection - Effective July 4, 2021
This Local Coverage Determination (LCD) has completed the Open Public Meeting comment period and is now finalized under contractor numbers: 02101 (AK), 03101 (AZ), 02201 (ID), 03201 (MT), 03301 (ND), 02301 (OR), 03401 (SD), 03501 (UT), 02401 (WA), and 03601 (WY).
|Medicare Coverage Database Number||LCD Title|
|L38671||MolDX: Molecular Testing for Solid Organ Allograft Rejection|
|Medicare Coverage Database Number||Billing and Coding Article|
|A58170||Billing and Coding: MolDX: Molecular Testing for Solid Organ Allograft Rejection|
Effective Date: July 4, 2021
Summary: Limited coverage for molecular diagnostic tests used in the evaluation and management of patients who have undergone solid organ transplantation. These tests can inform decision making along with standard clinical assessments in their evaluation of organ injury for active rejection (AR).
Visit the Future LCDs webpage to access this LCD.
Last Updated Wed, 26 May 2021 20:03:31 +0000